10.1002/mnfr.202300286 12 BudnowskiJ.HanskeL.SchumacherF.GlattH.PlatzS.RohnS.et al (2015)
10.1038/s41598-021-97967-0 Summary Keywords heart failure, GLP-1, glucagon-like peptide-1, clinical trials, cardiovascular disease, cardiovascular outcome studies, diabetes, obesity Citation Kreiner FF, Hovingh GKK and von Scholten BJ (2022) The potential of glucagon-like peptide-1 receptor agonists in heart failure
It also plays a critical role in maintaining cellular health by directly neutralizing free radicals, as well as by maintaining the activity of vitamins C and E
The result is a new wave of digital therapeutics, metabolic health programs, and integrated care models that promise a more balanced approach to chronic disease management
A paper in science journal PLoS One found no evidence of flashbacks (such as hallucinations or panic attacks) from sole mushroom use